Z Gastroenterol 2016; 54(12): 1343-1404
DOI: 10.1055/s-0036-1597464
4. Tumors/Liver Surgery
Georg Thieme Verlag KG Stuttgart · New York

Cux1 confers resistance to apoptotic cell death in liver cancer cells

E Hofmann
1   Philipps University Marburg, Department of Visceral, Thoracic and Vascular Surgery, Marburg, Germany
,
P Di Fazio
1   Philipps University Marburg, Department of Visceral, Thoracic and Vascular Surgery, Marburg, Germany
,
DK Bartsch
1   Philipps University Marburg, Department of Visceral, Thoracic and Vascular Surgery, Marburg, Germany
,
T Gress
2   Philipps University Marburg, Department of Gastroenterology, Marburg, Germany
,
TT Wissniowski
2   Philipps University Marburg, Department of Gastroenterology, Marburg, Germany
› Institutsangaben
Weitere Informationen
Di Fazio, Pietro

Publikationsverlauf

Publikationsdatum:
19. Dezember 2016 (online)

Auch verfügbar auf
 
 

    Background and Aims: CUX1 (CUTL1) is a transcription factor able to promote the expression of several genes implicated in cellular proliferation, differentiation and demise. In normal adult cells, it preferentially favors the expression of proapoptotic genes. Its aberrant expression in tumor turns its role as foe. Here, we analyze CUX1 activity in TRAIL (Tumour necrosis factor related apoptosis inducing ligand) mediated cell death in liver cancer cells.

    Methods: CUX1 was knocked down in HepG2 and Hep3B cells. Cells were further treated for 48 hours with a strong ligand (superkiller) binding DR4 and DR5 (TRAIL death receptors). The cell death events were analyzed by FACS analysis. RT-qPCR was performed to detect the expression of apoptotic markers. Caspase activity was measured by luminescence. Apoptosis array was performed.

    Results: Treatment with superkiller TRAIL, at 50 and 100 ng/ml, caused cell death in HepG2 and Hep3B cells after 48h proven by an accumulation of 40% of sub-G1 events. CUX1 knock down caused a sensitization of liver cancer cells to TRAIL effect by increasing, significantly, the percentage of sub-G1 events (60% with 100 ng/ml). CUX1 knock down did not change the expression of TP53, KRT18, CDKN1A and CDKN1B. Interestingly, silencing CUX1 increased the activity of caspase 3/7 after treatment with soluble TRAIL. The effect was neutralized by pan-caspase inhibitor zVAD. Apoptosis array evidenced an increased protein level of un-/cleaved caspase 3 after CUX1 knock down.

    Conclusions: CUX1 mediates the resistance of liver cancer cells to TRAIL signaling. Knock down of CUX1 restores the potential of TRAIL to trigger cell death.


    #

    Die Autoren geben an, dass kein Interessenkonflikt besteht.

    Di Fazio, Pietro